Account
Inquiry
Tirzepatide 10mg is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist currently under investigation for type 2 diabetes treatment and weight management applications.
Our tirzepatide 10mg formulation demonstrates superior efficacy in glucose control compared to selective GLP-1 receptor agonists. The compound's unique structure features a lysine side chain with PEG modification, enhancing water solubility while maintaining biological activity.
In clinical trials, tirzepatide 10mg has shown remarkable results, with participants achieving average weight reductions of 19.5% after 72 weeks of treatment. This positions tirzepatide as a promising candidate for metabolic disorder research.
The mechanism of action involves simultaneous activation of both GIP and GLP-1 receptors, creating synergistic effects that may offer advantages over single-receptor agonists. Researchers are particularly interested in tirzepatide's potential to address both glycemic control and weight management in a single therapeutic approach.
For laboratory use, our tirzepatide 10mg is supplied in sterile vials with guaranteed 99.9% purity. Each batch undergoes rigorous quality control testing to ensure consistency and reliability for research applications.
Storage recommendations include maintaining the product in a cool, dry environment protected from light. Researchers should aliquot the material according to experimental requirements to preserve stability.
This product is intended for research purposes only and not for human consumption. Proper laboratory handling procedures should always be followed when working with tirzepatide 10mg or any research compounds.
